What GISTT-RACE is, and what it is for.
The GIST Research Alliance for CurE (GISTT-RACE) is a collaboration of medical oncologists, surgeons, radiation oncologists, pathologists, radiologists, basic and translational scientists and patient organizations, established in 2025 following the GISTT Summit 2024 in Essen, with the following aims:
No field in oncology owes more to the partnership between academic researchers and industry than GIST. Imatinib, sunitinib, regorafenib, ripretinib and avapritinib came out of it, and so did the trials that showed when to stop, when to continue and when to operate. GISTT-RACE wants that partnership to continue, as a partnership between equals.
Companies are welcome as members and as partners in projects and trials; they bring compounds, trial expertise and resources that academic groups do not have. What they do not bring is the question. The alliance decides what is asked, how it is analyzed and what is published; project boards disclose their interests, and nobody sits on a board that judges data on their own product.
The support that fits this best is the unrestricted grant: money given to the questions, not to the answers. Companies that support GISTT-RACE this way are named as supporters. Their support buys no seat on a scientific board and no say in a result.
From the institutions of the GISTT Summit 2024, membership has grown to 25 institutions in 12 countries across Europe, North America and Asia, together with the patient organizations that supported the Summit. The GISTT Summit is the central working-group meeting of the alliance.
To get in touch, please write to info@gistt-race.org.
“The most effective way to do it is to do it.”attributed to Amelia Earhart, aviation pioneer